Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Vitamin D receptor binding, chromatin states and association with multiple sclerosis.
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.
Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
Laquinimod for multiple sclerosis.
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
[The influence of locomotor treatment using robotic body-weight-supported treadmill training on rehabilitation outcome of patients suffering from neurological disorders].
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Ono to enter license agreements with Merck KGaA
Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.
Cranial neuropathies in multiple sclerosis defined by magnetic resonance imaging and fludeoxyglucose f 18 positron emission tomography.
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection-a case report.
Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis.

Pages